RxDoctor Payments Data

Alexander Culbreth, MD

Obstetrics & Gynecology · Valdosta, GANPI 1447336185

Payments from drug & device makers

$6,194in general payments, 2019–2025

Across 290 payments — averaging $21.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • AbbVie$660
  • Intuitive Surgical$650
  • Amgen$555
  • Pfizer$384
  • Shield Therapeutics Inc$330
  • plus $3K from 46 others

What the payments were for

  • Travel & lodging$3385%
  • Food & beverage$5,66191%
  • Education$1953%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,194 in reported general payments places this provider in the 90th percentile of 1,324 obstetrics & gynecology providers in Georgia.

See all obstetrics & gynecology providers in Georgia

Medicare billing

Part B allowed, 2024
$165,218
Medicare patients
374
Services billed
5,500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron39$20,165
MounjaroTirzepatide19$19,656
GemtesaVibegron23$14,806
Estradiol226$14,452
PremarinEstrogens, Conjugated43$12,673
OsphenaOspemifene30$8,868
VeozahFezolinetant12$6,208
Raloxifene Hcl162$5,649
Ibandronate Sodium103$3,105
DottiEstradiol18$1,909
ValacyclovirValacyclovir Hcl46$1,590
Risedronate Sodium18$1,138
Solifenacin Succinate20$974
Estradiol (Twice Weekly)Estradiol15$893
Oxybutynin Chloride ErOxybutynin Chloride47$819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq, Veozah$1,041$26,37251 claims
Lilly USA, LLCMounjaro$49$19,65619 claims
Sumitomo Pharma America, Inc.Gemtesa$180$14,80623 claims
PfizerPremarin$384$12,67343 claims
Duchesnay USA IncorporatedOsphena$38$8,86830 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,324 obstetrics & gynecology providers in Georgia.

Other obstetrics & gynecology in Valdosta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →